Full Press Release Details
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Leading oncology journal accepts for publication new CEL-SCI Multikine Phase 3 data.
CVM Positive Sentiment
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
Key Takeaway: CEL-SCI's Multikine Phase 3 data has been accepted for publication in a leading oncology journal. This study demonstrates an overall survival benefit for patients with head and neck cancer, particularly those from underserved populations. The publication marks a significant milestone for CEL-SCI in showcasing the effectiveness of its treatment.
Market Sentiment Analysis
POSITIVE FACTORS
- New data accepted for publication in a leading oncology journal.
- Demonstrated overall survival benefit in underserved patients.
- Highlights the effectiveness of CEL-SCI's Multikine treatment.
Frequently Asked Questions
What is the significance of the new Multikine data?
The new Multikine data demonstrates an overall survival benefit for underserved head and neck cancer patients.
Which journal accepted the Multikine Phase 3 data?
The data has been accepted for publication in a leading oncology journal.
What type of cancer does Multikine target?
Multikine targets head and neck cancer patients.
Who conducted the Multikine Phase 3 study?
The study was conducted by CEL-SCI Corporation.